HCWB logo

HCW BIOLOGICS INC

HCWBNASDAQ
🏆 #5462 by market capEarnings Nov 12US Equity
$1.83▼ $0.07 (−3.95%)
Live
🔔
Track HCWB
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 4.0%
7d▼ 0.3%
14d▼ 11.0%
30d▼ 46.2%
ytd▼ 69.3%
1y▼ 92.2%
🏦Market Cap
$634,445
Small Cap
📈Revenue Growth (YoY)
-97.9%
Declining
📊Gross Margin
95.9%
High
💵FCF Margin
-180.6%
Thin
⚖️P/S Ratio
0.1x
Cheap
Otter Score
88
Very Good

Trading Snapshot

Day Range
$1.81 – $1.84
52-Week Range
$1.50 – $29.28
Volume
$3.05B
Avg Volume
$2.15B
Shares Outstanding
347,641
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$54,232
Last Q Revenue
$135,568
P/E Ratio
-0.0
P/S Ratio
0.1x
EPS (TTM)
$-14.08
Dividend Yield
0.00%
Dilution (1yr)
−94.6%

Why Investors Own HCWB

  • ✓High-growth profile — revenue up +58.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 63% gross margin and 16% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

HCWB logo

HCW BIOLOGICS INC

HCWB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$54K▼ −97.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
20.0%▼ −46.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −61.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$13M▼ −7.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
350K▼ −94.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$5M▲ +$4M YoY
StockOtter · stockotter.space

About HCW BIOLOGICS INC

HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Very Good
88/100

Analyst Price Target

ⓘ
Average Target
$1.82
▼ −0.5% Downside
High Target$1.96
Low Target$1.55
Based on 32 analysts

Latest News & Updates

🚀
Reuters·2h ago

HCW BIOLOGICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift HCWB price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

HCW BIOLOGICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.